my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Micromet hat integrated expertise and infrastructure to move its candidates more
Amgen and Micromet, Inc.announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany, for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously more
Micromet, Inc. announced that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, more
Micromet, Inc. announced the initiation of a phase 2 trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed t more
Do you want to find market prospects for products and companies in the biological drugs industry? Our new report shows you biopharma revenue forecasts for 2011 to 2021. We provide original research, data and opinions to benefit your work now. What revenues will biopharmaceutical markets achieve fro more
What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more
The Company Products & Technologies PR and Publications Career Company News HUENENBERG and ZURICH, Switzerland – September 14, 2009 Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases more
Home Font Size: 1 2 3 Send to a Friend Company Mission History About Us Awards Contact Driving Directions Technology Product Pipeline MORAb-004 Farletuzumab MORAb-009 Preclinical Pipeline Clinical Trials Farletuzumab MORAb-004 MORAb-009 Partnerships Research Alliances News & Even more
Press Release ESBATech AG Wagistr. 21 CH-8952 Zurich-Schlieren Switzerland Phone +41-1-733 4900 Fax +41-1-733 4990 Zurich, Switzerland, 31 August 2004 ESBATech’s antibody screening technology patent granted by the European Patent Office ESBATech AG (ESBATech) announced today that th more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
